Stuart Peltz compensation by year
PTC THERAPEUTICS Summary Compensation Table · all 8 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Salary | $618,000 | $636,540 | $658,819 | $702,000 | $742,000 | $768,750 | $791,833 | $188,033 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $242,568 | $0 | $0 | $1,688,280 | $1,835,124 | $1,676,400 | $2,089,260 |
| Option awards | $3,354,908 | $974,423 | $2,421,961 | $6,316,691 | $7,163,426 | $7,550,900 | $3,946,800 | $2,773,225 |
| Non-equity incentive | $260,000 | $302,357 | $922,347 | $723,950 | $835,300 | $835,300 | $720,600 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $9,603 | $16,795 | $13,608 | $16,800 | $123,786 | $32,249 | $28,107 | $608,866 |
| Total | $4,242,511 | $2,172,683 | $4,016,735 | $7,759,441 | $10,552,792 | $11,022,323 | $7,163,740 | $5,659,384 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PTC THERAPEUTICS, INC. DEF 14A filed April 26, 2024, accession 0001558370-24-005924, and prior-year filings. Open the filing on EDGAR.
How this page was built: the PTC THERAPEUTICS, INC. filed document, accession 0001558370-24-005924. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 27,600 | $1,099,308 | — |
| RSU | 24,750 | $985,793 | — |
| Option | 12,500 | — | $18.01 |
| Option | 82,813 | — | $33.02 |
| Option | 55,000 | — | $33.02 |
| Option | 108,282 | — | $51.16 |
| Option | 161,000 | — | $66.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in PTC THERAPEUTICS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
PTC THERAPEUTICS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Matthew Klein | Chief Executive Officer | $8,937,025 |
| Stuart Peltz · this page | Former Chief Executive Officer | $5,659,384 |
| Pierre Gravier | Chief Financial Officer | $2,734,475 |
| Eric Pauwels | Chief Business Officer | $2,412,590 |
| Lee Golden | Executive Vice President and Chief Medical Officer | $2,394,995 |
| Emily Hill | Former Chief Financial Officer | $2,259,089 |
| Mark Boulding | Executive Vice President and Chief Legal Officer | $2,190,788 |
| Neil Almstead | Chief Technical Operations Officer | $2,174,776 |
Board service
PTC THERAPEUTICS board · FY2021How this board is paid
Company policy: PTC THERAPEUTICS pays directors a $50,000 cash retainer. As stated in PTC THERAPEUTICS's FY2021 proxy.
The full PTC THERAPEUTICS compensation record
free company briefThis page is one person within PTC THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the PTC THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PTC THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.